Clinical trials: Atorvastatin, completed
Hyperlipidemia
Clinical Study to Evaluate Antihyperlipidemic Effect of a Classical Unani Antiobesity Formulation
The purpose of this clinical trial is to study the comparative effect of a classical unani antiobesity drug safoof-e-muhazzil on hyperlipidemia in its classical powder form and in compressed tablet form against a standard control.
- Trial name
- NCT01332747
- Testing
- safoof e muhazzil, compressed tablet of safoof e muhazzil, Atorvastatin
- Where
- India
- Volunteers
- 128 people, healthy volunteers welcome
- Sponsor
- Jamia Hamdard University
Healthy
A Study of LY900020 in Healthy Chinese Participants
This study will evaluate three new formulations of LY900020; a fixed dose, combination drug developed for people with type 2 diabetes mellitus.
- Trial name
- NCT04047940
- Testing
- LY900020, Metformin XR, Atorvastatin
- Where
- Singapore
- Volunteers
- 32 people, healthy volunteers welcome
- Sponsor
- Eli Lilly and Company
Acute Kidney Injury
Safety and Efficiency Study of Loading Dose Atorvastatin in Cardiac Surgery
Statins were reported to have pleiotropic effects including antiinflammatory, anti-oxidative stress effects and stabilise plaque in some conditions.
- Trial name
- NCT01547455
- Testing
- Atorvastatin(Lipitor)
- Where
- China
- Volunteers
- 96 people
- Sponsor
- Peking Union Medical College
Hypercholesterolemia
Evaluate Safety and Efficacy of AEGR-733 and Atorvastatin vs Atorvastatin Monotherapy in Hypercholesterolemia
Evaluate the efficacy of combination therapy AEGR-733 plus atorvastatin 20 mg versus monotherapy on serum lipoproteins over 4 and 8 weeks of therapy.
- Trial name
- NCT00690443
- Testing
- Atorvastatin, AEGR-733
- Where
- 5 sites in United States
- Volunteers
- 44 people, healthy volunteers welcome
- Sponsor
- Aegerion Pharmaceuticals, Inc.
Diabetes Mellitus, Type 1
Prediction and Prevention of Asymptomatic Cardiovascular Insult in Type 1 Diabetic Children: Comparative Effectiveness of Cardioprotective Drugs
Diabetic cardiomyopathy (DCM) is a distinct clinical entity of diabetic heart muscle that describes diabetes associated changes in the structure and function of the myocardium in the absence of coronary artery disease…
- Trial name
- NCT03660293
- Testing
- Atorvastatin, Captopril, L-carnitine
- Where
- Egypt
- Volunteers
- 150 people, healthy volunteers welcome
- Sponsor
- Tanta University
Furcation Defects
PRF+1% MF for Class II Mandibular Furcation Defects
The aim of the present trial is to evaluate the efficacy of PRF with 1% MF in treatment of mandibular class II furcation defects and its comparison to PRF and access therapy alone.
- Trial name
- NCT03207698
- Testing
- Open flap debridement (OFD), OFD with Platelet rich fibrin (PRF), OFD with Platelet rich fibrin (PRF)+1% Metformin (Drug) in gel form
- Where
- India
- Volunteers
- 75 people, healthy volunteers welcome
- Sponsor
- Government Dental College and Research Institute, Bangalore
Diabetes Mellitus, Type 2, Vascular Inflammation
The Effect of Statin Treatment on Arterial Wall Inflammation as Assessed With 68Ga-DOTATATE PET-CT
To study the effect of atorvastatin treatment on vascular uptake of 68Ga-DOTATATE in patients with Type 2 Diabetes.
- Trial name
- CARAMEL (NCT05730634)
- Testing
- Atorvastatin 40 Mg Oral Tablet
- Where
- Netherlands
- Volunteers
- 24 people
- Sponsor
- Academisch Medisch Centrum - Universiteit van Amsterdam (AMC-UvA)
Breast Cancer
A Clinical Trial to Compare Efficacy and Tolerability of Atorvastatin in Addition to Endocrine Treatment With Focus on Mechanisms of Resistance to Endocrine Treatment (Fulvestrant/Aromatase Inhibitors) in Patients With Advanced Breast Cancer
A Clinical Trial to Compare Efficacy and Tolerability of Atorvastatin in Addition to Endocrine Treatment with Focus on Mechanisms of Resistance to Endocrine Treatment (fulvestrant/aromatase inhibitors) in Patients With Advanced…
- Trial name
- ABC-SE (NCT02958852)
- Testing
- Letrozole, Letrozole and atorvastatin, Fulvestrant
- Where
- Sweden
- Volunteers
- 126 people
- Sponsor
- Lund University Hospital
Hypercholesterolemia
Ezetimibe/Simvastatin (10 mg/40 mg) vs. the Doubling of Atorvastatin in High Risk Participants (MK-0653A-134 AM1)(COMPLETED)
Participants currently taking atorvastatin 20 mg will be switched to either atorvastatin 40 mg or ezetimibe/simvastatin 10 mg/40 mg (10/40).
- Trial name
- NCT00782184
- Testing
- ezetimibe/simvastatin 10/40, atorvastatin 40 mg, atorvastatin 20 mg
- Volunteers
- 250 people
- Sponsor
- Organon and Co
Muscular Diseases
Differences in Atorvastatin Metabolite Ratios as a Diagnostic Tool in Detecting Atorvastatin Induced Myotoxicity
The primary objective of the study is to investigate whether differences in atorvastatin metabolite ratios might have a positive or negative predictive value in diagnosing atorvastatin muscle toxicity.
- Trial name
- NCT00199745
- Testing
- atorvastatin
- Where
- Norway
- Volunteers
- 53 people, healthy volunteers welcome
- Sponsor
- Oslo University Hospital
Alveolar Socket Preservations
Socket Augmentation Using Platelet Concentrates, Atorvastatin Gel or Combination
This study was conducted to compare post-extraction augmented sockets using Atorvastatin loaded in Plasma rich in growth factors derived fibrin scaffold (PRGF/ATV) or direct application of Atorvastatin (ATV) gel or platelet rich…
- Trial name
- NCT03231137
- Testing
- PRGF/ATV, ATV gel, PRF
- Volunteers
- 50 people, healthy volunteers welcome
- Sponsor
- Ain Shams University
Diabetes Mellitus, Type 2
A Study of LY3549492 in Participants With Type 2 Diabetes Mellitus (T2DM)
The main purpose of this study is to evaluate the safety and tolerability of LY3549492 in participants with T2DM. Blood tests will be done to check how much LY3549492 gets into the bloodstream and how the body handles LY3549492.
- Trial name
- NCT05327595
- Testing
- LY3549492, Atorvastatin, Midazolam
- Where
- Germany
- Volunteers
- 80 people
- Sponsor
- Eli Lilly and Company
Hypercholesterolemia
Efficacy and Safety Evaluation of Alirocumab (SAR236553/REGN727) When Co-administered With High Dose of Atorvastatin in Patients With Primary Hypercholesterolemia
Primary Objective: To evaluate the effect of alirocumab (SAR236553/REGN727) on low-density lipoprotein cholesterol (LDL-C) levels compared with placebo when co-administered with 80 mg of atorvastatin after 8 weeks of treatment in…
- Trial name
- NCT01288469
- Testing
- Alirocumab, Atorvastatin
- Where
- 20 sites in United States
- Volunteers
- 92 people
- Sponsor
- Sanofi
Hypercholesterolemia
Korean Rosuvastatin Effectiveness Study in Nondiabetic Metabolic Syndrome
The primary objective of this study is to compare the effect of rosuvastatin 10mg with atorvastatin 10mg in the percentage reduction of LDL-C in Subjects with metabolic syndrome after 6 weeks of treatment.
- Trial name
- NCT00335699
- Testing
- Rosuvastatin
- Where
- 7 sites in South Korea
- Volunteers
- 370 people
- Sponsor
- AstraZeneca
Cerebral Cavernous Malformation
Atorvastatin Treatment of Cavernous Angiomas With Symptomatic Hemorrhage Exploratory Proof of Concept (AT CASH EPOC) Trial
This phase I/II randomized, placebo-controlled, double-blinded, single-site clinical trial is designed to investigate the effect of a prolonged course of atorvastatin versus placebo on CCM lesional iron deposition assessed by…
- Trial name
- AT CASH EPOC (NCT02603328)
- Testing
- Atorvastatin
- Where
- United States
- Volunteers
- 80 people
- Sponsor
- University of Chicago
Furcation Defects
Platelet Rich Fibrin+1.2% Atorvastatin in Treatment of Mandibular Degree II Furcation Defects
The present study was designed to explore the effectiveness of PRF combined with 1.2% ATV gel in treatment of mandibular degree II furcation defects in comparison to PRF and open flap debridement (OFD) alone.
- Trial name
- NCT02612792
- Testing
- Open flap debridement (OFD), OFD with Platelet rich fibrin (PRF), OFD with Platelet rich fibrin (PRF)+1.2% Atorvastatin (Drug) in gel form
- Where
- India
- Volunteers
- 82 people, healthy volunteers welcome
- Sponsor
- Government Dental College and Research Institute, Bangalore
Essential Hypertension, Primary Hypercholesterolemia
A Study to Evaluate the Efficacy and Safety of BR1017A and BR1017B Combination Therapy in Essential Hypertension Patients With Primary Hypercholesterolemia
The objective of this clinical study is to evaluate the efficacy and safety by comparing BR1017A+BR1017B treatment group to BR1017A treatment group and BR1017B treatment group respectively at Week 8 in essential hypertension…
- Trial name
- NCT05930028
- Testing
- Fimasartan, Ezetimibe/Atorvastatin
- Where
- South Korea
- Volunteers
- 148 people
- Sponsor
- Boryung Pharmaceutical Co., Ltd
Acute Coronary Syndrome
Plaque Regression and Progenitor Cell Mobilization With Intensive Lipid Elimination Regimen (PREMIER), Phase I
The purpose of this randomized, multi-site, clinical trial is to determine whether intensive therapy consisting of cholesterol-lowering statin drugs plus apheresis to cleanse the blood of low-density lipoprotein (LDL) cholesterol…
- Trial name
- PREMIER (NCT01004406)
- Testing
- intensive LDL-lowering therapy, standard statin monotherapy
- Where
- 2 sites in United States
- Volunteers
- 59 people
- Sponsor
- VA Office of Research and Development
Diabetes Mellitus, Type 2, Coronary Artery Disease
Effect of RVX000222 on Time to Major Adverse Cardiovascular Events in High-Risk T2DM Subjects With CAD
The purpose of this study is to determine whether bromodomain extraterminal domain (BET) inhibition treatment with RVX000222 in high-risk type 2 diabetes mellitus patients with coronary artery disease increases the time to major…
- Trial name
- BETonMACE (NCT02586155)
- Testing
- Apabetalone, Atorvastatin, Rosuvastatin
- Where
- 214 sites in Argentina, Australia and 13 more
- Volunteers
- 2,425 people
- Sponsor
- Resverlogix Corp
Hypercholesterolemia
Efficacy and Safety Evaluation of Alirocumab in Patients With Heterozygous Familial Hypercholesterolemia or High Cardiovascular Risk Patients With Hypercholesterolemia on Lipid Modifying Therapy (ODYSSEY JAPAN)
Primary Objective: To demonstrate the reduction of low-density lipoprotein cholesterol (LDL-C) by alirocumab as add-on therapy to stable daily statin therapy with or without other lipid modifying therapy in comparison with…
- Trial name
- NCT02107898
- Testing
- Alirocumab, Lipid-Modifying Therapy (LMT)
- Where
- 32 sites in Japan
- Volunteers
- 216 people
- Sponsor
- Sanofi